Department of Pediatrics, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Regional Newborn Screening Laboratory of Lombardy Region, Children's Hospital V. Buzzi, Milan, Italy.
J Clin Endocrinol Metab. 2021 Jan 1;106(1):e338-e349. doi: 10.1210/clinem/dgaa789.
Analysis of a 2-screen program for congenital hypothyroidism (CH) was performed using differential dried-blood spot thyrotropin (bTSH) cutoffs of 10 mU/L at first screening (all infants) and 5 mU/L at second screening (selected infants).
This work aimed to characterize CH infants identified by the second screening and compare infants with bTSH of 5.0 to 9.9 and 10 mU/L or greater on second screening.
Maternal and neonatal clinical features were retrospectively analyzed for 119 CH babies detected on the second screen in the Lombardy region of Italy, 2007 to 2014.
Fifty-two (43.7%) of the 119 CH neonates showed bTSH values ranging from 5.0 to 9.9 mU/L at the second screening (low bTSH group) and 67 (56.3%) bTSH of 10.0 mU/L or greater (high bTSH group). The frequency of thyroid dysgenesis and eutopic gland was similar in both groups, as was the frequency of permanent and transient CH. Moreover, a high frequency of extrathyroidal malformations was found in both groups. The percentage of preterm infants (57.7% vs 23.9%, P < .001) and infants admitted to the neonatal intensive care unit (50.0% vs 17.9%, P < .001) was significantly higher in the low vs the high bTSH group. In addition, maternal treatment with glucocorticoids in pregnancy was significantly more frequent in the low bTSH group than in the high bTSH group (11.5% vs 1.5%, P = .042), as well as maternal hypothyroidism and/or goiter (26.9% vs 10.4%, P = .036).
This study has demonstrated that a lower TSH cutoff at the second screening can detect additional cases of CH and that a second bTSH cutoff of 5.0 mU/L is appropriate for identifying preterm newborns and babies with associated risk factors.
对先天性甲状腺功能减退症(CH)的 2 屏幕程序进行分析,使用在初次筛查(所有婴儿)时的 10 mU/L 和在二次筛查(选择的婴儿)时的 5 mU/L 的差异干血斑促甲状腺激素(bTSH)截止值。
本研究旨在描述通过二次筛查识别出的 CH 婴儿,并比较二次筛查时 bTSH 为 5.0 至 9.9 和 10 mU/L 或更高的婴儿。
回顾性分析了 2007 年至 2014 年意大利伦巴第地区在二次筛查中发现的 119 例 CH 婴儿的母婴临床特征。
119 例 CH 新生儿中有 52 例(43.7%)在二次筛查时 bTSH 值在 5.0 至 9.9 mU/L 之间(低 bTSH 组),67 例(56.3%)bTSH 值为 10.0 mU/L 或更高(高 bTSH 组)。两组的甲状腺发育不良和异位腺体的频率相似,永久性和暂时性 CH 的频率也相似。此外,两组均发现甲状腺外畸形的发生率较高。早产儿(57.7%比 23.9%,P<0.001)和入住新生儿重症监护病房(50.0%比 17.9%,P<0.001)的婴儿比例在低 bTSH 组明显高于高 bTSH 组。此外,低 bTSH 组母亲在妊娠期间接受糖皮质激素治疗的比例明显高于高 bTSH 组(11.5%比 1.5%,P=0.042),以及母亲甲状腺功能减退症和/或甲状腺肿(26.9%比 10.4%,P=0.036)。
本研究表明,在二次筛查时使用较低的 TSH 截止值可以检测到更多的 CH 病例,并且将二次 bTSH 截止值设为 5.0 mU/L 是合适的,可以识别早产儿和有相关危险因素的婴儿。